NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Perceive Biotherapeutics, Inc.

Perceive Biotherapeutics, Inc.

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://perceivebio.com/

Last Round

Series B

Jan 5, 2023

Total Funding Raised

$78M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Perceive Biotherapeutics, Inc. is a biotechnology company that develops gene therapies and other innovative therapeutics for the treatment of ocular diseases such as age-related macular degeneration and glaucoma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyophthalmologyclinical-stage biotechocular diseasebiotech startupclinical trialsdrug developmentvision restorationbiopharmatherapeutic pipelineR&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Perceive Biotherapeutics, Inc. Comps

Public and private peers based on sector, stage, and business model.

Perceive Biotherapeutics, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Perceive Biotherapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 5, 2023
Series AAug 1, 2018

Key People

Founding team and executive leadership

K. Angela Macfarlane

Chief Executive Officer

Executive Team

Ranjit Ahluwalia

Chief Financial Officer

Executive Team

Perceive Biotherapeutics, Inc. Investors

Notable investors and investment history

Perceive Biotherapeutics, Inc. investors
InvestorRounds
Deerfield ManagementSeries A, Series B
BraidwellSeries B
Catalio Capital ManagementSeries B
Foundation Fighting BlindnessSeries B
Johnson & Johnson Innovation – JJDCSeries B
Johnson & Johnson Innovation - JJDC, Inc.Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 98% MoM.

  • Dec 1, 2025

    Lead gene therapy program in ophthalmology enters Phase 2 trials.

Perceive Biotherapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Perceive Biotherapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Perceive Biotherapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range23
Year Founded2020
Last FundingJan 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.